ResMed
RMD
687 hedge funds and large institutions have $14.3B invested in ResMed in 2023 Q4 according to their latest regulatory filings, with 112 funds opening new positions, 247 increasing their positions, 241 reducing their positions, and 74 closing their positions.
51% more first-time investments, than exits
New positions opened: 112 | Existing positions closed: 74
10% more capital invested
Capital invested by funds: $13B → $14.3B (+$1.25B)
5% more funds holding
Funds holding: 657 → 687 (+30)
2% more repeat investments, than reductions
Existing positions increased: 247 | Existing positions reduced: 241
3.3% less ownership
Funds ownership: 59.67% → 56.37% (-3.3%)
32% less call options, than puts
Call options by funds: $110M | Put options by funds: $162M
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$178M |
| 2 |
LCP
LGT Capital Partners
Pfaeffikon,
Switzerland
|
+$105M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
+$91.8M |
| 4 |
ZIG
Zurich Insurance Group
Zurich,
Switzerland
|
+$70.3M |
| 5 |
Jane Street
New York
|
+$67.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$229M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$197M |
| 3 |
Two Sigma Investments
New York
|
-$119M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$101M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$96.3M |
RMD Hedge Fund Activity: Q4 2023 in Review
687 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q4 2023, worth a combined $14.3B — up 9.6% from $13B a quarter earlier.
Buyers outnumbered sellers: 112 funds opened new RMD positions and 74 closed out — a net gain of 38 holders — while 247 added to existing stakes and 241 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $178M. The largest seller was Citadel Advisors, cutting an estimated $229M.
- 687 institutional investors held ResMed (RMD) as of Q4 2023, up from 657 in Q3 2023.
- Funds reported $14.3B of ResMed stock for Q4 2023, up 9.6% quarter-over-quarter.
- 112 funds opened new ResMed positions in Q4 2023 and 74 closed out, a net change of +38 holders.
- The largest ResMed buyer in Q4 2023 was Morgan Stanley, an estimated $178M added.
- The largest ResMed seller in Q4 2023 was Citadel Advisors, an estimated $229M sold.
Based on aggregated 13F filings for Q4 2023.